The positive opinion from CHMP regarding Sirturo is a critical regulatory milestone for Johnson & Johnson, likely leading to increased market confidence and potential sales growth for this specific treatment. Given the global need for effective treatments against multidrug-resistant tuberculosis, this approval could significantly impact JNJ's pharmaceutical segment, enhancing its reputation and financial performance in the short term.